A Durham-based biotechnology company secured $6.5 million in funding and aims to raise another $6.5 million, according to a Securities and Exchange Commission filing.
Cell Microsystems last week acquired Fluxion Biosciences, a life sciences company headquartered in Oakland, California. Both Cell Microsystems and Fluxion develop products for cellular analysis.
The acquisition was made with the support of concurrent Series B financing from Telegraph Hill Partners, a California-based venture capital and growth equity firm focused on the life sciences industry.
The Fluxion team will join Cell Microsystems, according to a press release.
Cell Microsystems’ CEO has been Gary Pace since 2014. According to the Cell Microsystems website, Pace is “looking forward to further expansion of the company” to grow its portfolio.
He previously worked as a patent attorney and corporate counsel for Durham-based Oncoscope, a medical device company.
Cell Microsystems was founded by three UNC Chapel Hill researchers in 2010.
